Gyre Therapeutics, Inc. Segment Expenditure Addition To Long Lived Assets
Gyre Therapeutics, Inc. (GYRE) reported Segment Expenditure Addition To Long Lived Assets of $440.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Segment Reporting
us-gaap:SegmentExpenditureAdditionToLongLivedAssets · last filed 2026-08-07
- Gyre Therapeutics, Inc. segment expenditure addition to long lived assets for the quarter ending 2026-06-30 was $262.00K, a 21.79% decline year-over-year.
- Gyre Therapeutics, Inc. segment expenditure addition to long lived assets for the quarter ending 2026-03-31 was $178.00K, a 45.90% increase year-over-year.
- Gyre Therapeutics, Inc. segment expenditure addition to long lived assets for the quarter ending 2025-12-31 was $144.00K.
- Gyre Therapeutics, Inc. segment expenditure addition to long lived assets for the quarter ending 2025-09-30 was $589.00K, a 15.01% decline year-over-year.
- Gyre Therapeutics, Inc. segment expenditure addition to long lived assets for fiscal 2025 was $1.19M, a 48.60% decline from fiscal 2024.
- Gyre Therapeutics, Inc. segment expenditure addition to long lived assets for fiscal 2024 was $2.31M, a 72.82% decline from fiscal 2023.
- Gyre Therapeutics, Inc. segment expenditure addition to long lived assets for fiscal 2023 was $8.52M, a 70.85% increase from fiscal 2022.
- Gyre Therapeutics, Inc. segment expenditure addition to long lived assets for fiscal 2022 was $4.99M.
| Period end | Segment Expenditure Addition To Long Lived Assets 3 month | Segment Expenditure Addition To Long Lived Assets 6 month | Segment Expenditure Addition To Long Lived Assets 6 month as first filed | Segment Expenditure Addition To Long Lived Assets 9 month | Segment Expenditure Addition To Long Lived Assets 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $262.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $440.00K 10-Q · filed 2026-08-07 | $584.00K derived: sum of 3 quarters · filed 2026-08-07 | $1.17M derived: sum of 4 quarters · filed 2026-08-07 | |
| 2026-03-31 | $178.00K 10-Q · filed 2026-05-08 | $322.00K derived: sum of 2 quarters · filed 2026-05-08 | $911.00K derived: sum of 3 quarters · filed 2026-05-08 | $1.25M derived: sum of 4 quarters · filed 2026-08-07 | |
| 2025-12-31 | $144.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $733.00K derived: sum of 2 quarters · filed 2026-03-13 | $1.07M derived: sum of 3 quarters · filed 2026-08-07 | $1.19M 10-K · filed 2026-03-13 | |
| 2025-09-30 | $589.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $924.00K derived: sum of 2 quarters · filed 2026-08-07 | $1.05M 10-Q · filed 2025-11-07 | $981.00K derived: sum of 4 quarters · filed 2026-08-07 | |
| 2025-06-30 | $335.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $457.00K 10-Q · filed 2026-08-07 | $378.00K 10-Q · filed 2025-08-11 | $392.00K derived: sum of 3 quarters · filed 2026-08-07 | $1.08M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $122.00K 10-Q · filed 2026-05-08 | $57.00K derived: sum of 2 quarters · filed 2026-05-08 | $750.00K derived: sum of 3 quarters · filed 2026-05-08 | $2.21M derived: sum of 4 quarters · filed 2026-05-08 | |
| 2024-12-31 | -$65.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $628.00K derived: sum of 2 quarters · filed 2026-03-13 | $2.08M derived: sum of 3 quarters · filed 2026-03-13 | $2.31M 10-K · filed 2026-03-13 | |
| 2024-09-30 | $693.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $2.15M derived: sum of 2 quarters · filed 2025-11-07 | $2.38M 10-Q · filed 2025-11-07 | $4.70M derived: sum of 4 quarters · filed 2025-11-07 | |
| 2024-06-30 | $1.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $1.69M 10-Q · filed 2025-08-11 | $4.01M derived: sum of 3 quarters · filed 2025-08-11 | $5.99M derived: sum of 4 quarters · filed 2025-08-11 | |
| 2024-03-31 | $231.00K 10-Q · filed 2025-05-09 | $2.56M derived: sum of 2 quarters · filed 2025-05-09 | $4.53M derived: sum of 3 quarters · filed 2025-05-09 | $7.01M derived: sum of 4 quarters · filed 2025-05-09 | |
| 2023-12-31 | $2.32M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $4.30M derived: sum of 2 quarters · filed 2025-03-17 | $6.78M derived: sum of 3 quarters · filed 2025-03-17 | $8.52M 10-K · filed 2025-03-17 | |
| 2023-09-30 | $1.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $4.45M derived: sum of 2 quarters · filed 2024-11-13 | $6.19M 10-Q · filed 2024-11-13 | ||
| 2023-06-30 | $2.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $4.22M 10-Q · filed 2024-08-13 | |||
| 2023-03-31 | $1.74M 10-Q · filed 2024-05-13 | ||||
| 2022-12-31 | $4.99M 10-K · filed 2024-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |